His laboratory employs a multifaceted array of experimental models of aging and age-related neurodegenerative disorders in order to establish the cellular and biochemical changes that occur during aging and in disorders such as Alzheimer's, Parkinson's, and stroke. In addition to identifying the molecular and cellular alterations that lead to neuronal degeneration in age-related neurological diseases, his group is elucidating the cellular and biochemical signaling mechanisms that allow successful brain aging. They are also running drug discovery projects spanning the range from target validation and initial high-throughput screening to lead identification to advance the discovery of new, efficacious therapies for the treatment, delay of progression, or prevention of Alzheimer’s disease, mild cognitive impairment, age-related cognitive decline, and stroke.